BioNTech SE (BNTX)
NASDAQ: BNTX
· Real-Time Price · USD
99.26
1.38 (1.41%)
At close: Sep 16, 2025, 3:59 PM
99.09
-0.17%
Pre-market: Sep 17, 2025, 06:43 AM EDT
1.41% (1D)
| Bid | 99 |
| Market Cap | 23.86B |
| Revenue (ttm) | 2.88B |
| Net Income (ttm) | -347.44M |
| EPS (ttm) | -1.69 |
| PE Ratio (ttm) | -58.73 |
| Forward PE | -23.08 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 100.47 |
| Volume | 1,110,463 |
| Avg. Volume (20D) | 820,645 |
| Open | 98.30 |
| Previous Close | 97.88 |
| Day's Range | 97.92 - 100.77 |
| 52-Week Range | 81.20 - 131.49 |
| Beta | 1.40 |
| Ex-Dividend Date | n/a |
About BNTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BNTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BNTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsBioNTech SE is scheduled to release its earnings on
Nov 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 days ago
-7.26%
Vaccine stocks are trading lower after a report in...
Unlock content with
Pro Subscription
1 week ago
-8.71%
BioNTech shares are trading lower. The company and Bristol Myers Squibb presented interim data from global randomized phase 2 trial evaluating Pumitamig an investigational bispecific antibody targeting PD-L1 X VEGF-A, plus chemotherapy in ES-SCLC patients.
